– Interview with Martin Peitz, by Aleksandra Boutin: Available for all (see above)
– Video: Available for Concurrences+ subscribers (see below)
– Audio: Available for Concurrences+ subscribers (see above)
– Synthesis: Available for Concurrences+ subscribers (see above)
– Transcript: Available for Concurrences+ subscribers (see above)
– Concurrences Related Articles (Click Read More below and see page’s bottom) Check the Upcoming Conferences section for the next webinars.
Deni Mantzari introduced the panel mentioning that perhaps no issue had received more attention in antitrust circles in recent years than killer acquisitions. First arising in the context of pharmaceutical transactions, scrutiny has now extended to other industries, with a particular focus on acquisitions in the technology sector. There have been calls for changes in the evidentiary standard for assessing so-called killer acquisitions, from the adoption of a balance-of-powers approach to the reversal of the burden of proof in such cases, motivated by the concern that the potential harm from killer acquisitions in the technology sector might be so important that it warrants an adjustment of the standards that are usually employed in competition cases.